BioSpace News Archive

IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metastatic triple negative breast cancer (TNBC) patients

Bovie Medical is a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market.

The Tumor Treating Fields plus gemcitabine and nab-paclitaxel patient cohort showed progression free and one-year survivals that were more than double those of the gemcitabine and nab-paclitaxel-treated historical control

Dramatic competitive actions by both of the two largest U.S. pharmacy retailers in the same month could be a good sign for the market for in vitro diagnostics, according to market research firm Kalorama Information.

DenMat Holdings, LLC (“DenMat”) announces the launch of the newly redesigned DenMat.com.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of data from two clinical trials for PEGPH20 (pegvorhyaluronidase alfa) in patients with advanced pancreas and metastatic breast cancer.

Home State Health in collaboration with its parent company, Centene Corporation, has recognized Dr. Robert Strashun, with a national award that acknowledges the extraordinary efforts made to provide quality care and clinical excellence to Home State Health members.

Qpex Biopharma today announced the closing of a $33 million Series A financing and launch of the infectious disease company.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of an €8 million disbursement from the European Investment Bank (EIB).

AirXpanders, Inc. (ASX: AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today announced publication of a study describing early clinical results of a treatment planning method for patients undergoing post mastectomy radiation therapy (PMRT)